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Our previous studies demonstrated that urine contains DNA derived from the circula-
tion and that this DNA originated, in part, from organ sites and tumors distal to the
urinary tract. To explore the potential use of DNA from urine as compared to other
body fluids as a source for circulating DNA for cancer detection, the DNA concentration
and the frequency of detection of mutated Kristin-ras (K-ras) DNA in serum, plasma,
and urine were examined. The concentration of DNA in the urine was similar to that
in the serum, but the DNA concentration in plasma was significantly lower than in
either urine or serum (P < 0.05). When DNA derived from 10 μL of body fluid was
used in each mutation assay, the detection frequency of mutated K-ras DNA was com-
parable among serum, plasma, and urine. However, when DNA derived from 200 μL
of body fluid was used, the incidence of detecting mutated K-ras DNA in urine was
significant higher (95%) than in either serum (35%) or plasma (40%) (P < 0.0005), sug-
gesting that inhibitory factors in serum /plasma may be more limiting than in urine.
The use and practicality of urine as a source of circulating DNA for cancer detection are
discussed.
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Introduction
Urinalysis for tumor DNA has been sug-
gested for detection of tumors located in or
close to the urinary tract, such as kidney or
bladder cancer.1–7 We8 and others9,10 have
shown that short-length, tumor-derived DNA
from non–urinary tract can be filtered through
the kidney barrier and can be excreted into
urine. Two distinct size categories of DNA can
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be noted by ethidium bromide–stained agarose
gel electrophoresis of total urine DNA, as previ-
ously described.8 They are the high-molecular-
weight (MW) DNA, which was derived from
sloughed-off urinary tract cells, and the low-
MW DNA that was previously suggested to be
mostly derived from the circulation.8 Thus, we
reason that analysis of DNA in urine should not
be limited to the diseases of the urinary tract,
but could also be a valuable tool for virtually ev-
ery cancer entity with known DNA alterations.
Potential applications of urine DNA anal-
ysis are similar to those expected from the
analysis of plasma DNA11–20 and include can-
cer screening, cancer detection, monitoring of
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tumor growth, evaluation of the effectiveness
of tumor chemotherapy or radiation therapy,
and monitoring of tumor recurrence. Urine col-
lection is an absolutely noninvasive procedure,
can be done in remote geographic areas, and
requires no special facility or equipment apart
from sterile collection containers, as compared
to the requirements for serum or plasma collec-
tion. The amount of urine that can be collected
from patients readily exceeds the amount of
serum or plasma normally collected. Thus, it
was of interest to explore the potential of using
urine in the area of noninvasive cancer screen-
ing or detection.
We have previously used the K-ras codon 12
mutation as a marker for circulating DNA to
demonstrate that genetic alterations that oc-
curred in the colon could be detected in urine.8
To further evaluate the potential of using urine
as a source of circulating DNA for detection of
colorectal cancer (CRC) biomarkers, we com-
pared the DNA quantity in the blood (serum
and plasma) and urine, and the incidence of de-
tection of mutated K-ras DNA in serum, plasma
and urine from individuals with a diagnosis of
colorectal disease containing K-ras mutations.
The K-ras mutation was chosen for two rea-
sons: (1) this is an important DNA biomarker
for CRC21–24 and adenomatous polyps,25–27 a
precursor of colon cancer, and (2) the incidence
of K-ras gene mutation occurring in cancer of
the urinary tract is rare.28 Thus, mutated K-ras
DNA can be used as a representative of a mu-
tation occurring at a tumor site outside of the
urinary tract. Here we report that the ability to
detect mutated K-ras DNA in urine could be
significantly higher than in serum or plasma of
patients with known K-ras mutations in their
disease tissues, when a larger volume (200 μL)
of body fluid is used in the assay.
Materials and Methods
Study Subjects and Selection
Participants were recruited from the Great
Lakes–New England Clinical Epidemiologi-
cal Center, which includes the University of
Michigan, Dana-Farber Harvard Cancer Cen-
ter, M.D. Anderson Cancer Center, and the
University of Toronto. Cancer patients were
enrolled from the surgical or oncological ser-
vices (prior to initiation of chemo- or radiation
therapy or surgery). Patient samples were ob-
tained under IRB strictures.
Collection of Body Fluid
Urine Collection
Urine samples were collected from patients
during office visits. Freshly collected urine was
immediately mixed with 0.5 M EDTA, pH 8.0
to a final concentration of 10 mM EDTA, in
order to inhibit possible nuclease activity in the
urine sample; this was stored at −70◦C. To
isolate total urine DNA, frozen urine samples
were thawed at room temperature, and then
placed immediately on ice prior to DNA iso-
lation. Thawed urine was processed for DNA
isolation within an hour.
Serum and Plasma Collection
Fifty milliliters of blood were collected in
heparinized containers from informed and
consenting subjects. The samples were permit-
ted to sit at room temperature for a minimum of
30 minutes (and a maximum of 60 minutes) to
allow the clot to form in the red-top tubes; they
were then centrifuged at 1,300 × g at 4◦C for
20 minutes. The serum or plasma was trans-
ferred to a polypropylene capped tube, and
frozen on dry ice.
DNA Isolation
Five milliliters (mL) of urine samples were
mixed with 1.5 volume of 6M guanidine thio-
cyanate (Sigma, St. Louis, MO, USA) by in-
verting eight times. One milliliter of resin
(Wizard Plus Mini-Prep DNA Purification
System, Promega, Madison, WI, USA) was
added into the urine lysate and incubated
overnight at room temperature with gentle mix-
ing. The resin–DNA complex was centrifuged,
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transferred to a mini-column (provided from
the kit), and washed with a buffer provided by
the manufacturer. Then, the DNA was eluted
with H2O. 0.5 mL of serum and plasma DNA
was isolated, as for urine, except for using a
2.5 volume of 6M guanidine thiocyanate. DNA
from paraffin-embedded tissue sections was iso-
lated using the MasterPure DNA Kit (Epicen-
tre, Madison, WI, USA) according to the man-
ufacturer’s instruction.
K-ras Codon 12 Mutation Assay
A restriction enriched polymerase chain re-
action (RE-PCR) described previously8,29 was
used to assay for mutated K-ras DNA. In
brief: 20 cycles of Hot-Start PCR were per-
formed as follows: DNA, with 1.5 mM MgCl2,
1× PCR buffer (Qiagen, Valencia, CA, USA),
0.5 U Hot-Start Taq (Qiagen), 200 μM dNTP,
0.1 μM primers [L-Ext (5′ GCT CTT CGT
GGT GTG GTG TCC ATA TAA ACT TGT
GGT AGT TGG ACC T 3′) and R-Ext (5′ gct
ctt cgt ggt gtg gtg tcc cgt cca caa aat gat tct
ga 3′)] were mixed and denatured at 95◦C for
15 min; this was followed by 20 cycles at 94◦C,
30 sec; 52◦C, 30 sec; and 1 cycle at 72◦C for
5 min. After the first round of PCR, the am-
plified products were digested with BstNI (New
England Biolab, Beverly, MA, USA) to elimi-
nate amplified products derived from wild-type
DNA. 1/20 of digested product was then sub-
jected to the second Hot-Start PCR with the
1 μM primers L-Bst (5′ ACT GAA TAT AAA
CTT GTG GTA GTT GGA CCT 3′) and
R-Bst (5′GTC CAC AAA ATG ATC CTG
GAT TAG C 3′) under the following conditions:
95◦C, 15 min; 40 cycles at 94◦C, 30 sec; 56◦C,
30 sec; and 1 cycle at 72◦C 5 min. The ampli-
fied products (87 bp) of the second PCR were
digested to completion with BstNI (as shown
by disappearance of the 87-bp DNA frag-
ment), and resolved through polyacrylamide
gels. Each sample was assayed 2–3 times. The
samples were scored as “positive” for K-ras mu-
tation when the 71-bp DNA fragment appeared
after the second BstNI digestion of the PCR
products in 2 of 2 or 2 of 3 repeated assays. As
validation controls, HepG2 cell DNA, contain-
ing wild-type K-ras reconstituted with various
amounts of K-ras codon 12–mutated SW480
DNA, was included in each assay.
Size Fractionation of Urine DNA
and DNA Quantification
Total urine DNA was fractionated by 2%
agarose gel electrophoresis. The agarose slices
corresponding to desired ranges of DNA
sizes were excised and subjected to DNA
isolation using the QIAquick Gel Extraction
Kit (Qiagen) and resuspended in 20 μL of
H2O. DNA was quantified by real-time PCR
using K-ras Q-primers (forward: 5′ AGG CCT
GCT GAA AAT GAC TG 3′, reverse: 5′ TTG
GAT CAT ATT CGT CCA CAA 3′, product
size of 116 bp), with the hybridization probes
(0.15 μM Sensor LC Red640-TTG CCT
ACG CCA CAA GGT CCA a-P; 0.3 μM
Anchor CCA CAA AAT GAT TCT GAA
TTA GCT GTA TCG TCA AGG CAC-X).
These quantification reactions were performed
using the LightCycler thermocycler (Roche
Biochemical, Mannheim, Germany) at 95◦C
for 10 min, 45 cycles at 95◦C for 5 s, 70◦C
for 15 s, 55◦C for 10 s, and 72◦C for 10 s. As
calibrators for quantification, serially diluted
genomic DNA was used.
Results
The Quantity of DNA in Urine, Serum,
and Plasma from Each Individual
Previously, we and others have suggested that
urine can be a source for circulating DNA.8,29
Thus, it was of interest to compare the sensi-
tivity of detecting genetic mutations in urine
with that of two other body fluids, plasma
and serum, that have been extensively used as
a source of circulating DNA. The circulating
DNA marker chosen in this study is mutated
K-ras DNA, which occurs rarely in tumors of
the urinary tract.28 In order to compare the
incidence of K-ras mutations in three body
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TABLE 1. Study Subjects and Detection of Mutated K-ras DNA in Urine, Serum, and Plasma of Each
Subject
Total DNAb Mutant K-rasd
(ng/mL body fluidc) Urine/Serum/Plasma
Patienta Urine Serum Plasma 200 μLe 10 μLe Diagnosis/Gender/Age
1 < 1.5 6.7 < 1.5 +/−/+ −/−/− CRC/M/73
2 1.9 94.8 5.8 +/+/− −/+/+ CRC/M/85
3 7.2 6.2 < 1.5 +/+/− +/−/− CRC/M/69
4 < 1.5 19.2 14.6 +/+/− −/+/+ CRC/F/70
5 18.7 20.9 1.8 +/+/− +/+/+ CRC/F/57
6 62.2 171.8 1.5 +/−/− +/−/+ CRC/F/76
7 5.4 11.2 < 1.5 +/−/− −/−/− CRC/M/87
8 15.1 1.7 4.1 +/−/+ +/+/+ Adnms/F/53
9 26.1 4.1 3.2 +/−/+ −/−/− Adnms/F/55
10 3.3 1.8 8.1 +/+/+ −/+/+ Adnms/M/70
11 14.4 3.1 7.6 +/−/− +/+/+ Adnms/F/67
12 2.7 95.1 < 1.5 +/−/− −/−/− Adnms/F/67
13 138.3 4.2 15.1 −/+/− −/−/− Adnms/F/63
14 18.3 11.3 5.8 +/−/+ +/−/+ Adnms/M/66
15 2.2 24.2 < 1.5 +/−/− −/−/+ Adnms/M/73
16 33.5 107.2 12.9 +/−/− −/−/+ Adnms/F/57
17 34.9 55.8 21.4 +/+/− +/−/− Adnms & Hypl/M/51
18 26.8 12.7 9.9 +/−/+ +/−/− Adnms & Hypl/M/59
19 25.1 < 1.5 27.3 +/−/+ −/−/− Adnms & Hypl/M/50
20 31.1 7.7 2.8 +/−/+ −/−/+ Adnms & Hypl/F/84
aPatients were recruited under IRB approval from the Great Lakes–New England Clinical Epidemiological Center
led by Dr. Brenner, University of Michigan, Ann Arbor, MI. The disease tissue of each patient was known to contain
K-ras mutation and the mutation was verified by K-ras RE-PCR assay as described in Materials and Methods on
the DNA isolated from the paraffin-fixed tissue specimens.
bDNA concentration (ng/mL) of each body fluid was determined by real-time PCR assay using albumin primers as
previously described.30 The limit of the quantitation was 0.015 ng/μL/rxn and was calculated as 1.5 ng/mL of body
fluid. “<1.5” represents the DNA concentration below the level of detection.
cThree body fluids, urine, serum, and plasma, from each individual were collected under IRB approval.
d The samples scored as “+” or “−” for K-ras mutation by RE-PCR assays were described in the Materials and
Methods section.
eThe amount of DNA used in each assay was derived from either 200 μL or 10 μL of each body fluid.
CRC = colorectal cancer; Adnms = adenomatous polyps; Hypl = hyperplasia.
fluids, we used the body fluids from 20 patients
having known mutant K-ras colorectal diseases
(adenomatous ployps with or without hyper-
plastic polyps, or colorectal cancer). The diag-
nosis, gender, and age information of the hu-
man subjects used in this study are listed in
Table 1. The existence of the K-ras mutation in
the diseased tissue was first verified by perform-
ing RE-PCR K-ras mutation assay, as described
in the Materials and Methods section (data not
shown).
It was first of interest to determine the
DNA yield from the three body fluids—urine,
serum, and plasma. Three body fluids from
each individual were collected according to the
IRB-approved protocol. Total DNA was iso-
lated and quantified by real-time PCR using
primers specific for the albumin gene, as de-
scribed previously.30 The limit of the assay was
1.5 ng/mL body fluid. The DNA concentra-
tions in each body fluid from different individ-
uals are listed in Table 1 and summarized in
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Figure 1. Comparison of DNA concentration in
urine, plasma, and serum from 20 individuals. DNA
was isolated from urine, plasma, and serum from
20 individuals diagnosed with K-ras mutated CRC
or adenomatous polyps as described in Materials
and Methods. Every data point represents the DNA
concentration (ng/mL) from each individual specimen
as determined by real-time PCR using the albumin
primers. The average (the bar and the number) of
DNA concentrations for each body fluid is also indi-
cated.
Figure 1 along with the average DNA
concentration of each body fluid from 20
individuals. The concentration of DNA in urine
and serum varied widely among individuals,
ranging from <1.5 ng/mL (the limit of detec-
tion) to 200 ng/mL of body fluid. In contrast,
the DNA concentration detected in plasma
fell within a narrower range (<1.5 ng/mL to
30 ng/mL).
To compare the DNA concentrations of
these three body fluids, the Kruskal–Wallis
test of ANOVA was performed. This anal-
ysis showed there were statistical differences
(P = 0.046). To compare the DNA concentra-
tion between any two body fluids, the matched-
pairs Wilcoxon test was performed. The P-
values were 0.4524, 0.01755, and 0.004285
for urine versus serum, serum versus plasma,
and urine versus plasma, respectively. The P-
values suggest that the concentration of DNA
in plasma is significantly lower than that in
urine or serum (P < 0.05), but there was no
significant difference between the DNA con-
centration in urine and in serum (P = 0.4524).
Collectively, the DNA concentration in plasma
is significantly less than that in serum or urine;
the DNA concentrations between serum and
urine were not significantly different.
Incidence of Detection of Mutated
K-ras DNA
Since the DNA concentration varied across
a wide range, and might be complicated by
how much cell debris was collected in urine or
serum, to compare the ability to detect mutated
K-ras DNA in three body fluids, a certain vol-
ume of each body fluid, instead of an absolute
amount of DNA (ng DNA), was used in each
mutation assay. DNA derived from two differ-
ent volumes, 10 μL or 200 μL, was subjected to
an RE-PCR K-ras mutation assay as described
in Materials and Methods. The RE-PCR as-
say for mutated K-ras DNA is a qualitative as-
say with an assay sensitivity of 2 copies/input
sample. The results are listed as positive (+),
representing ≥ 2 copies of mutated K-ras DNA
detected, or negative (−) for less than 2 copies
of mutated DNA present in the input DNA
(Table 1). Analysis of the results is summarized
in Table 2.
When 10 μL of serum, plasma, or urine was
used, mutated K-ras was detected in approxi-
mately 35–40% of the samples (Table 2). When
DNA derived from 200 μL of body fluid was
used in each assay, the incidence of mutated K-
ras DNA in urine was 19 of 20 samples, or 95%.
In contrast, when 200 μL, instead of 10 μL,
of serum or plasma was used, the incidence of
mutated K-ras DNA was still only 35% to 40%.
Using increased volumes of serum and plasma
did not improve the efficiency of detection of
mutated K-ras, and the reasons for this are con-
sidered in the discussion.
If 200 μL of body fluid was used in each as-
say, the ability to detect mutated K-ras DNA us-
ing DNA isolated from urine was significantly
higher than that of serum and plasma, with
P-values of 0.00014 and 0.00043, respectively,
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TABLE 2. Detection of Mutated K-ras DNA in Body Fluids from 20 Patients with Detectable K-ras
Mutation in Colorectal Disease Tissues
200 μL body fluid 10 μL body fluid
Urine Serum Plasma Urine Serum Plasma
No. of samples detected 19 7 8 8 6 11
Percent of detection 95% 35% 40% 40% 30% 55%
P-value – 0.00014 0.00043 – 0.741 0.527
DNA derived from 200 μL or 10 μL of urine, plasma, and serum of each individual was subjected to RE-PCR
K-ras mutation assay. Statistical analysis was performed by the Fisher exact two-tailed test. The P-values were
obtained as compared to the results of urine to serum or urine to plasma.
as determined by the Fisher exact two-tailed
test. If 10 μL of fluid was used, the detection
frequency of mutated K-ras DNA in urine
(40%), serum (30%), and plasma (55%) was
comparable. These data suggest that urine
could be a better source of circulating DNA
for detecting K-ras mutations as compared to
serum or plasma, if a larger volume of body
fluid can be used in the assay.
Distribution of Mutated K-ras DNA in
Size-Fractionated Urine DNA
We have previously shown that mutated K-
ras DNA was more concentrated in the subpop-
ulation of urine DNA ranging from 100 bp to
400 bp compared with the urine DNA larger
than 1 kb. To more comprehensively study the
size-wise distribution of mutated K-ras DNA
in the urine, we fractionated total urine DNA
from two patients (A and B) into 10 fractions
by agarose gel electrophoresis as described in
Materials and Methods. The urine DNA from
these two patients was chosen because of the
high amount of mutated K-ras DNA present
in their urine specimens. 1.0 μL of each frac-
tion (prepared as described in Materials and
Methods) was subjected to DNA quantifica-
tion by real-time PCR using K-ras Q-primers
and to K-ras mutation assay by RE-PCR as de-
scribed in Materials and Methods. The DNA
quantification using K-ras Q-primers instead
of albumin primers was to determine the num-
ber of DNA templates that contain the K-ras
gene sequences. The results are summarized in
Table 3.
As expected, the mutated K-ras DNA was en-
riched in lower-MW DNA fractions (less than
700 bp). Surprisingly, although the number of
DNA templates that contained K-ras gene se-
quences in the fraction of less than 150 bp was
below the limit of detection [0.015 ng (or 2
copies)/μL/rxn] by real-time PCR quantifi-
cation, mutated K-ras DNA was detected in
this fraction from both patients by RE-PCR
(≥2 copies/rxn). In addition to the small frag-
mented DNA fractions, mutated K-ras DNA
was also detected in the fraction of ≥10 kb
DNA. There was no detectable mutated K-
ras DNA in the fractions ranging from 1 kb
to 10 kb. Collectively, these data indicate that
the majority of mutated K-ras DNA detected in
urine was less than 700 bp.
Discussion
The possibility of using circulating DNA iso-
lated from serum or plasma in the diagnosis and
prognosis of disease has been explored exten-
sively.11,13–18,31–33 Less is known about urine-
derived DNA. In this study, we compared, for
the first time, how volumes of body fluids can
influence the sensitivity of detection of specific
mutations in the DNA derived from those flu-
ids. Mutated K-ras DNA was used as a marker
for colorectal disease–derived DNA, and urine,
serum, and plasma–derived DNAs were com-
pared for the frequency of mutation detection.
The results suggest that urine could be a better
source than serum or plasma for detecting mu-
tated circulating DNA for diagnosis of disease.
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TABLE 3. Distribution of Mutated K-ras DNA in Fractionated Urine DNA in Two Patients
Patient A Patient B
DNA concentration Mutated K- DNA concentration Mutated K-
Fractions (ng/μL) ras DNA (ng/μL) ras DNA
<150 bp ND + ND +
150–300 bp 0.010 + 0.016 +
300–500 bp 0.013 + 0.043 +
500–700 bp 0.024 + 0.043 +
700 bp–1 kb ND + 0.013 −
1–1.5 kb ND − 0.010 −
1.5–2 kb 0.016 − ND −
2–3 kb ND − ND −
3–4 kb ND − ND −
4–10 kb ND − ND −
10 kb–well 0.03 + ND +
DNA concentration was determined by the real-time PCR assay using K-ras Q-primers as described in Materials
and Methods. The limit of detection of the assay is 0.010 ng/μL/rxn; ND: below the limit of detection.
Mutated K-ras DNA was detected by RE-PCR (≥2copies per reaction). The positive sign (+) shows that the mutated
DNA was detected and the negative (−) indicates that the mutated K-ras DNA was not detected.
This was demonstrated by a significantly higher
incidence of detecting mutated K-ras DNA in
urine than in serum or plasma when DNA de-
rived from 200 μL of body fluid was used in
each assay.
It was interesting that the relative ability to
detect mutated K-ras DNA in urine, serum, and
plasma was very different with different vol-
umes of body fluid used in each assay. When
DNA derived from 10 μL of body fluid from
individuals with colorectal cancer or adeno-
matous polyps containing mutated ras proto-
oncogenes was used, the detection of mutated
K-ras DNA in urine, serum, and plasma was
comparable. Mutated ras was detected in each
body fluid approximately 40% of the time.
However, when DNA derived from 200 μL of
urine was used, the incidence of detecting mu-
tated K-ras DNA increased from 40% to 95%.
This was not the case for serum or plasma.
The efficiency in detecting mutated K-ras DNA
from 10 μL or 200 μL of serum or plasma was
similar.
It is possible that low levels of contaminants
exist in the DNA isolated from serum or plasma
that are either not present or are much less
abundant than in urine. In this model, the
amount of contaminants is low, such that their
interferences with PCR is limited in the small
volumes of sample, but becomes a much more
significant factor in larger amounts of plasma
or serum.
Previously, we reported that the sensitivity of
detection of circulating tumor DNA in serum
varied with the methods of DNA isolation.30
We found that methods that preferentially iso-
late small DNA provide better substrates for
detecting mutated K-ras DNA than methods
that do not discriminate between large and
small DNA. Urine contains small-MW circu-
lating DNA filtered through the kidney bar-
riers. Macromolecules, such as proteins, and
circulating long DNA, are retained in the circu-
lation under normal physiological conditions.
These macromolecules could possibly interfere
with PCR amplification. DNA isolated from
urine could be less contaminated with possible
PCR inhibitors as compared with DNA iso-
lated directly from the circulation; thus, the in-
cidence of detecting a target sequence increases
when a greater amount of the substrate is
used.
By monitoring the appearance of mutated K-
ras DNA in each fraction of the total urine DNA
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separated by size, we show that the size of DNA
derived from the circulation present in the urine
was predominately less than 700 bp. Of interest,
we can also detect a limited amount of mutated
K-ras DNA in two higher-MW DNA fractions
(larger than 700 bp, as shown in Table 2). It is
possible that this is due to an incomplete sepa-
ration of low MW from high MW by agarose
gel electrophoresis. The other possibility is that
the limited amount of mutated K-ras DNA de-
tected in higher-MW DNA fractions was in-
deed derived from high-MW DNA templates.
This would suggest that high-MW DNA can
pass through the kidney barrier, or be actively
transported into urine, or that the K-ras muta-
tion derives from the dying cells of the urinary
tract. There has been no evidence to distinguish
between these possibilities yet.
Although the amount of DNA in the fraction
less than 150 bp was below the level of detec-
tion by our real-time PCR assay, mutated K-ras
DNA was detected in this fraction from both
patients by RE-PCR. Note that the amplicon
generated in RE-PCR is only 76 nt, whereas the
amplicon generated by the K-ras Q-primers for
DNA quantification is 116 bp. Assuming circu-
lating DNA found in urine was generated by
random breakage, the possibility that a DNA
molecule in the fraction <150 bp contains both
RE-PCR primer sequences is higher than that
of K-ras Q-primer sequences. Therefore, it is
likely that the RE-PCR assay was more sen-
sitive because more templates contained se-
quences corresponding to both primers used in
this assay, even though some of these templates
would not be amplified by the K-ras Q-primers
in the quantification assay.
The quantity of circulating DNA in plasma
and serum has been shown to increase in pa-
tients with variety of medical conditions such
as autoimmune disease, chronic inflammatory
states, infectious disease, and cancer.20,34–38 In
addition, the circulating DNA concentration
can vary with methods of blood collection, pro-
cessing, and analysis. In order to investigate
whether the frequency of detecting the mutated
DNA in urine, serum, and plasma is associated
with the quantity of DNA, we compared the
quantity of genomic DNA among these three
body fluids. The concentration of DNA in urine
and serum varied widely among individuals,
ranging from undetectable to 200 ng/mL of
body fluid. In contrast, the DNA concentra-
tion detected in plasma is in a narrower range
(below the level of detection to 30 ng/mL).
These ranges are within those reported previ-
ously.20,32,35 Interestingly, our results indicate
that the quality rather than the quantity of
DNA might contribute to a significantly higher
detection rate (95%) of mutated K-ras DNA in
urine as compared to two other body fluids,
serum (35%) and plasma (40%), when DNA
isolated from a larger volume (200 μL) of body
fluid was used in each assay.
It has been suggested by several investiga-
tors that the major source for tumor-derived
circulating DNA is apoptotic cells and necrotic
cells.19,39,40 Apoptosis of tumor cells can be due
to the elimination of tumor cells by the immune
system or mutations of anti-apoptotic genes,
such as the K-ras gene. During the early stage of
carcinogenesis, the rate of apoptosis increased
as suggested.41–43 Of interest, a typical apop-
totic DNA pattern, a nucleosome-sized DNA
ladder, was observed for the DNA isolated from
the circulation previously by us8 and others.39
Studies by Jahr et al.39 suggested that the sizes of
DNA derived from necrotic cells were of higher
MW, approximately larger than 10 kb. Here, we
show that the circulating DNA found in urine
is most likely in sizes less than 700 bp; thus, the
DNA from necrotic cells might not be excreted
into urine unless further degradation of DNA
occurs in the circulation. This could be one
limitation of using urine DNA as a source for
circulating DNA if one requires the DNA sub-
strate from the necrotic cells. Nevertheless, the
presence of circulating tumor-derived DNA in
urine holds great promise, encouraging further
exploration of the potential of using urine DNA
biomarkers for noninvasive disease screening,
diagnosis, and prognosis.
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